Knee osteoarthritis. Gonarthrosis
Conditions
Interventions
Intervention 1: Alendronate tablet 70mg orally single dose/week (Alnate product of Dr. Abidi Company) for 24 weeks. Intervention 2: Placebo, one tablet orally per week for 24 weeks.
Placebo
Alendronate tablet 70mg orally single dose/week (Alnate product of Dr. Abidi Company) for 24 weeks.
Placebo, one tablet orally per week for 24 weeks
Sponsors
Vice Chancellor for Research, Mashhad University of Medical Science
Eligibility
Sex/Gender
All
Age
40 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: fulfilling the American College of rheumatology (ACR) criteria of primary knee osteoarthritis, radiologically ascertained grade I or II severity of OA of the knee on the Kellgren-Lawrence scale, having a Western Ontario and McMaster Universities (WOMAC) pain subscale index of at least 2 at baseline (the 5-point Linkert version of the WOMAC), presence of daily knee pain for at least 6 months preceding the study Exclusion criteria: Presence of secondary osteoarthritis, arthroscopy or surgery of target knee within 6 months prior to study, intra-articular treatment of target knee within 6 months prior to study, other chronic inflammatory processes, previous gastrointestinal problems (such as gastroesophageal reflux or esophageal stricture), previous allergic reactions to bisphosphonates, presence of any risk factors for osteoporosis
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in symptoms of knee osteoarthritis. Timepoint: Weeks 0, 4, 12, 24. Method of measurement: WOMAC Index. | — |
Secondary
| Measure | Time frame |
|---|---|
| Joint space narrowing. Timepoint: weeks 0 and 24. Method of measurement: Knee X-ray. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammadhassan Jokar
Mashhad University of Medical Sciences
Outcome results
None listed